CTI Clinical Trial and Consulting Services (CTI), a multi-national, privately held, full-service contract research organization has signed a Memorandum of Understanding (MOU) with Samsung Medical Center (SMC), located in Seoul, South Korea. The purpose of the Memorandum is to affirm both CTI's and SMC's commitment to identifying and developing opportunities for cooperation and collaboration in advancing clinical research in fields such as rare and orphan disease, regenerative medicine, and hematology/oncology. The Memorandum was signed by Patrick J. Earley, CTI's Chief International Business Officer and Ki Woong Sung, Director of Clinical Research Institute at SMC.
"We are thrilled to enter this strategic partnership with Samsung Medical Center," remarks Patrick J. Earley. "Samsung Medical Center is an innovative research site that is committed to bringing life-changing drugs to patients in need, just as CTI is. We have been working throughout the Asia-Pacific region for nearly a decade, and we have many successful collaborations throughout the region with leading academic centers and emerging biotechnology companies. CTI continues to grow steadily in the region, and we look forward to future accomplishments/efficiencies enabled by this partnership."
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Using Patient Reported Outcomes in Dermatology Trials
April 25th 2024In part 3 of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA sheds light on the unique challenges of dermatology trials and how clinical outcome assessments can be implemented in them.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.